Progress for Cystic Fibrosis Early Diagnosis
A new report shows steady progress in identifying cystic fibrosis earlier, with 67% of CF infants screened in 2024 within the first 28 days of life, compared to 60% in 2014.
Tag: CF foundation
All
Latest
Progress for Cystic Fibrosis Early Diagnosis
A new report shows steady progress in identifying cystic fibrosis earlier, with 67% of CF infants screened in 2024 within the first 28 days of life, compared to 60% in 2014.
Read More
Industry Pushes Congress to Pass SOAR Act Before Year’s End
Twenty-seven national healthcare organizations, including the American Lung Association, are pressing Congress to pass the Supplemental Oxygen Access Reform (SOAR) Act before adjourning for the year.
Read More
Industry Calls on Congress to Support SOAR Act
More than a dozen national organizations are pressing Congress to support the Supplemental Oxygen Access Reform (SOAR) Act, which would ensure Medicare patient access to life-saving oxygen therapy.
Read More
7 Recommendations for Cystic Fibrosis Newborn Screening
The CF Foundation’s Newborn Screening Committee developed a consensus guideline with seven recommendations to describe current best practices in newborn screening nationwide.
Read More
CFF Backs Breath Test for P. aeruginosa
Funding from the Cystic Fibrosis Foundation will support development of a breath test to diagnose Pseudomonas aeruginosa infections in CF patients.
Read More
CF Foundation Invests $15M in ReCode to Develop Gene Editing Therapy
The Cystic Fibrosis Foundation is funding the development of a gene editing therapy that is designed to use ReCode’s tissue-specific delivery vehicle to transport gene editing cargo to the lung cells in people with cystic fibrosis.
Read More
SpliSense Gets FDA Nod for Phase 2 Trial for Investigational CF Treatment
The trial will test the efficacy of SpliSense’s inhaled antisense oligonucleotide drug as a potential treatment for the lungs of people with cystic fibrosis with a certain splicing mutation.
Read More
Cystic Fibrosis Foundation Funds Prime Medicine’s Gene Editing Research
The Cystic Fibrosis Foundation will provide up to $15 million to Prime Medicine for preclinical research into gene editing for cystic fibrosis.
Read More
Cystic Fibrosis mRNA Therapeutic Candidate Gets Funding Boost
The Cystic Fibrosis Foundation is investing up to $9 million in additional funds in Arcturus Therapeutics to test ARCT-032, an inhaled messenger RNA therapeutic candidate that could treat the underlying cause of cystic fibrosis in all people living with the disease.
Read More
Cystic Fibrosis: Long-Term Antibiotics Not Needed in Patients Without Chronic P Aeruginosa
Outcomes don’t improve in cystic fibrosis patients given long-term inhaled antibiotics who do not have chronic Pseudomonas aeruginosa, a new study found.
Read More
Predicting Pediatric Cystic Fibrosis Events
The combined use of patient-reported symptom data and objective lung function measures may help manage acute respiratory events in pediatric CF patients.
Read More
Replica Shelby 427 Cobra Raffle to Support Cystic Fibrosis Research
The Ohio Cobra Club, a nonprofit organization of car enthusiasts in Ohio, will raffle off a replica Shelby 427 Cobra with proceeds donated to the Cystic Fibrosis Foundation.
Read More
Cystic Fibrosis Foundation Launches Inaugural Golden Ticket Competition to Find the Next Genetic Therapies for CF
The Cystic Fibrosis Foundation announced its first-ever Golden Ticket Competition to find the next promising treatment for cystic fibrosis in a collaboration with Bakar Labs, the incubator at the University of California, Berkeley’s Bakar BioEnginuity Hub.
Read More
CF Foundation Awards $1.6 Million to Improve Detection of Lung Transplant Complication
The Cystic Fibrosis Foundation announced $1.6 million in awards for eight research grants focused on early detection and diagnosis of chronic lung allograft dysfunction.
Read More
Study: Lung Function in Pediatric Cystic Fibrosis Patients Different in US vs UK
Pediatric patients with cystic fibrosis with the homozygous F508del genotype in the U.S. had better lung function than children in the U.K., data published in Thorax shows.
Read More
The Human Lung Airway Chip That Models Cystic Fibosis
A multidisciplinary research team at Harvard’s Wyss Institute for Biologically Inspired Engineering have developed a microfluidic organ chip device the size of a USB memory stick that recapitulates key pathological hallmarks from CF patients.
Read More
Antipseudomonal Antibiotics for Cystic Fibrosis
Cystic fibrosis patients experiencing pulmonary exacerbations do not have greater improvement after therapy with 2 intravenous antipseudomonal antibiotics versus a single antibiotic, according to new findings.
Read More
Study Uses Smartphone to Track Cystic Fibrosis
An observational study supported by the CF Foundation will monitor real-world experience with Trikafta.
Read More
Cystic Fibrosis Foundation Chief Scientific Officer to Retire
The Cystic Fibrosis Foundation’s chief scientific officer William Skach, MD, will retire this summer from his role at the foundation.
Read MoreCystic Fibrosis Antisense Oligonucleotide Therapy Gets Funding Boost
The biotech company SpliSense received an investment of up to $8.4 million from the Cystic Fibrosis Foundation to develop an antisense oligonucleotide (ASO) therapy for people with cystic fibrosis who have splicing mutations.
Read More
Cystic Fibrosis Foundation Reaffirms Support for COVID-19 Vaccination for CF Patients
The Cystic Fibrosis Foundation issued a statement encouraging people with cystic fibrosis to talk with their CF care team about getting vaccinated.
Read MoreCF Foundation Supporting Development of Malabsorption Syndrome Therapy
The Cystic Fibrosis Foundation is supporting the development of Synspira’s SNSP003, an orally-delivered non-porcine enzyme replacement therapy (ERT) designed to treat malabsorption syndromes.
Read More
CF Foundation Opposes Latest Version of Right to Try Act as Still Posing Risks
The Cystic Fibrosis Foundation (CFF) has joined 70 other organizations in signing a letter...
Read More
CF Foundation Grant to Fund Treatment for Bacterial Lung Infections
Aridis Pharmaceuticals has received an undisclosed grant to develop Panaecin (gallium citrate) to treat bacterial lung infections.
Read More